
    
      1. Primary objective To determine the maximum tolerated dose and the recommended dose for
           phase 2 clinical trial for the repeated administration of DHP107 (oral paclitaxel) on
           advanced solid cancer patients

        2. Secondary objectives

             -  To identify the dose limiting toxicity and the safety (toxicity) of DHP107

             -  To evaluate the efficacy (tumor response rate) of DHP107

             -  To assess pharmacokinetic (PK) characteristics of DHP107
    
  